#Decoy Therapeutics #peptide-conjugate #antiviral

Decoy Therapeutics Takes a Leap Towards Global Healthcare Accessibility

Decoy Therapeutics, Inc., a rising preclinical biopharmaceutical player listed on Nasdaq under the symbol DCOY, recently highlighted its commitment to global health through its participation in a virtual investor segment titled "What This Means." This segment detailed the company's newly established Global Access Commitment Agreement (GACA) in collaboration with the well-known Gates Foundation, showcasing Decoy's innovative approach in the field of peptide-conjugate therapeutics.

What is the Global Access Commitment Agreement?

The GACA signals Decoy’s dedication to developing a flexible and globally accessible manufacturing platform specifically for peptide-conjugate antivirals. The initiative is particularly focused on ensuring that these advanced therapeutics can be manufactured quickly and cost-effectively, thereby meeting the demands of emerging global health crises, especially in low- and middle-income countries.

During the segment, Peter Marschel, Decoy's Chief Business Officer, elucidated the company's strategic plan to transition peptide-conjugate therapeutics efficiently from laboratory settings to large-scale commercial production. This part of their manufacturing strategy is designed to build a robust global production network capable of responding effectively to viral threats, which have increasingly become a public health need.

Innovations in Peptide-Conjugate Therapeutics

Decoy's manufacturing platform boasts a unique approach referred to as